Inogen, Inc. announced preliminary, unaudited revenue results for the fourth quarter and full-year 2025. The total revenue in the fourth quarter of 2025 is approximately $82 million with a 2% year-over-year growth. For the full year 2025, total revenue is expected to be around $349 million, reflecting a 4% year-over-year growth.
The company is on track to achieve positive Adjusted EBITDA for the full year 2025, demonstrating its commitment to financial discipline and cost management.
Despite a few large customer orders shifting into the first half of 2026, the business continued to show strong performance in the business-to-business channels.
Revenue Growth
Total revenue in the fourth quarter of 2025 is estimated to be around $82 million, showing a 2% year-over-year increase.
Positive EBITDA
Inogen expects to achieve positive Adjusted EBITDA for the full year 2025, highlighting its focus on financial discipline.
Product Innovation
The company launched the Voxi 5 stationary oxygen concentrator and Aurora Masks for Obstructive Sleep Apnea patients in the U.S., advancing its innovation pipeline.
Business Outlook
Inogen remains confident in its growth acceleration and profitability prospects for 2026, with further details to be shared during the February earnings call.
- The delay in some customer orders may have affected the fourth quarter results, but the company's overall performance and growth trajectory remained positive throughout the year.
- Revenue growth, progress towards profitability, and expanding product offerings demonstrate Inogen's resilience and strategic focus on driving innovation and market expansion.
Inogen's preliminary revenue results for 2025 reflect steady growth and a focus on financial discipline. Despite challenges such as order delays, the company's commitment to innovation and profitability positions it well for the future.